The last paragraph of this article has been corrected to note that the $150 million in funding is in support of the Strategic Research Initiative.

NEW YORK (GenomeWeb) – Researchers at Indiana University have announced the launch of a new study in which they will use targeted sequencing provided by testing firm Paradigm to try to direct personalized treatment strategies for women with triple-negative breast cancer (TNBC) in the hopes of extending their lives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.